Immunological treatment of Multiple Sclerosis

Treatment of Multiple Sclerosis (MS) has been a challenge since its first description by Charcot. The advent of immunomodulatory drugs in the mid 90ies brought the first big change in the treatment of MS patients. During the last 10 years there has been an ongoing tremendous evolution of novel treatment options for relapsing-remitting MS. These options include monoclonal antibodies, which inhibit migration of lymphocytes (natalizumab), deplete lymphocytes (alemtuzumab), or block the cytokine receptor IL-2 (daclizumab), teriflunomide that inhibits proliferation of activated lymphocytes, fingolimod that modulates the sphingosine-receptor system, and dimethylfumarate that combines features of immunomodulatory and immunosuppressive drugs.
Source: Seminars in Hematology - Category: Hematology Authors: Tags: April 2016 Suppl 1 ICIS Source Type: research